Fibrinolytic and thrombolytic parameters in patients with deep vein thrombosis treated by low molecular weight and standard heparin.
Faivre
R
R
Service de Cardiologie et Laboratoire d'Hemostase, CHU St-Jacques, Besancon, France.
Neuhart
E
E
Mirshahi
M
M
Mirshahi
M
M
Soria
C
C
Soria
J
J
Bassand
J P
JP
Caen
J P
JP
Maurat
J P
JP
D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007118:Immunoassay; D010690:Phlebography; D011655:Pulmonary Embolism / Q000145:classification / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin